Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis

被引：2
|
作者：
Egan L.J. [1 ]
Sandborn W.J. [1 ]
机构：
[1] Department of Pharmacology, National University of Ireland, University College Hospital, Galway
来源：
Current Gastroenterology Reports | 2005年 / 7卷 / 6期
关键词：
Inflammatory Bowel Disease; Ulcerative Colitis; Infliximab; Adalimumab; Natalizumab;
D O I：
10.1007/s11894-005-0080-3
中图分类号：
学科分类号：
摘要：
Traditional medications for inflammatory bowel disease are small molecule drugs, most of which were developed for use in other diseases before being found to be efficacious for the treatment of ulcerative colitis or Crohn's disease. Recently, several exciting alternative approaches to the medical treatment of inflammatory bowel disease have been developed. These include biologic, probiotic, and apheresis therapies that offer certain advantages over traditional drug therapy for inflammatory bowel disease. The purpose of this review is to assess the current state of knowledge about novel biologic, probiotic, and apheresis therapies and to analyze how best to incorporate these therapies into evolving management paradigms of inflammatory bowel disease. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：485 / 491
页数：6
相关论文
共 50 条
  • [1] Positioning biologic therapy for Crohn's disease and ulcerative colitis
    Velayos F.S.
    Sandborn W.J.
    [J]. Current Gastroenterology Reports, 2007, 9 (6) : 521 - 527
  • [2] Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease)
    Marc Ferrante
    Geert D’Haens
    Paul Rutgeerts
    Séverine Vermeire
    Gert Van Assche
    [J]. Current Gastroenterology Reports, 2009, 11 (6) : 504 - 508
  • [3] Therapies for Crohn's disease and ulcerative colitis
    Aylett, P
    [J]. IDRUGS, 2006, 9 (07) : 452 - 454
  • [4] Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States
    Siegel, Corey A.
    Yang, Fei
    Eslava, Sergio
    Cai, Zhaohui
    [J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2020, 11 : e00128
  • [5] New biologic therapeutics for ulcerative colitis and Crohn's disease
    Mozaffari, Shilan
    Nikfar, Shekoufeh
    Abdolghaffari, Amir Hossein
    Abdollahi, Mohammad
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (05) : 583 - 600
  • [6] Advances in biologic therapy for ulcerative colitis and Crohn's disease
    D'Haens G.
    Daperno M.
    [J]. Current Gastroenterology Reports, 2006, 8 (6) : 506 - 512
  • [7] Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease
    O’Toole A.
    Moss A.C.
    [J]. Current Gastroenterology Reports, 2015, 17 (8)
  • [8] Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease
    Nguyen G.C.
    Harris M.L.
    Dassopoulos T.
    [J]. Current Gastroenterology Reports, 2006, 8 (6) : 499 - 505
  • [9] Medical therapies for ulcerative colitis and Crohn's disease.
    Baert F.J.
    Rutgeerts P.J.
    [J]. Current Gastroenterology Reports, 2000, 2 (6) : 446 - 450
  • [10] Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile
    Di Sario, Antonio
    Bendia, Emanuele
    Schiada, Laura
    Sassaroli, Paola
    Benedetti, Antonio
    [J]. CURRENT DRUG SAFETY, 2016, 11 (01) : 55 - 61
12345